- Home
- TNYA
as of 03-02-2026 10:51am EST
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 121.6M | IPO Year: | 2021 |
| Target Price: | $5.25 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.48 | EPS Growth: | 22.02 |
| 52 Week Low/High: | $0.36 - $2.35 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.19 | Index: | N/A |
| Free Cash Flow: | -91526000.0 | FCF Growth: | N/A |
AI-Powered TNYA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Tenaya Therapeutics Inc. (TNYA)
10% Owner
Avg Cost/Share
$0.56
Shares
3,511,826
Total Value
$1,975,050.94
Owned After
0
10% Owner
Avg Cost/Share
$0.62
Shares
658,440
Total Value
$405,138.13
Owned After
0
10% Owner
Avg Cost/Share
$0.60
Shares
306,000
Total Value
$182,743.20
Owned After
0
10% Owner
Avg Cost/Share
$0.61
Shares
523,734
Total Value
$322,044.04
Owned After
0
Chief Medical Officer
Avg Cost/Share
$0.64
Shares
5,160
Total Value
$3,318.72
Owned After
218,618
SVP, Finance
Avg Cost/Share
$0.64
Shares
3,469
Total Value
$2,231.35
Owned After
119,752
10% Owner
Avg Cost/Share
$0.68
Shares
4,056,573
Total Value
$2,761,714.90
Owned After
0
10% Owner
Avg Cost/Share
$0.82
Shares
343,717
Total Value
$280,507.44
Owned After
0
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 25, 2026 | Sell | $0.56 | 3,511,826 | $1,975,050.94 | 0 | |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 24, 2026 | Sell | $0.62 | 658,440 | $405,138.13 | 0 | |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 23, 2026 | Sell | $0.60 | 306,000 | $182,743.20 | 0 | |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 20, 2026 | Sell | $0.61 | 523,734 | $322,044.04 | 0 | |
| Tingley Whittemore | TNYA | Chief Medical Officer | Feb 17, 2026 | Sell | $0.64 | 5,160 | $3,318.72 | 218,618 | |
| Ali Faraz | TNYA | Chief Executive Officer | Feb 17, 2026 | Sell | $0.64 | 14,862 | $9,556.66 | 452,415 | |
| Higa Tomohiro | TNYA | SVP, Finance | Feb 17, 2026 | Sell | $0.64 | 3,469 | $2,231.35 | 119,752 | |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 11, 2026 | Sell | $0.68 | 4,056,573 | $2,761,714.90 | 0 | |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 10, 2026 | Sell | $0.82 | 343,717 | $280,507.44 | 0 |
Compare TNYA vs Leading Stocks
See how TNYA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TNYA Tenaya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.